KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kiniksa Pharmaceuticals International, plc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$79.48+0.89 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $6.55B
- P/E (TTM)
- 88.3
- Dividend yield
- –
Share price
+$40.84 (+105.7%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Kiniksa Pharmaceuticals International, plc grew revenue 56.7% to $754.05M over the twelve months to Mar 31, 2026. Free cash flow was $164.23M, up 275.5% from a year earlier.
Revenue
$754.05M
+56.7% vs. a year earlier
Operating income
$93.22M
TTM Q1 2026
Free cash flow
$164.23M
+275.5% vs. a year earlier
EPS, diluted
$0.90
TTM Q1 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $6.55B
- P/E ratio
- 88.3
- Price to sales
- 8.69
- Price to book
- 10.81
- Dividend yield
- –
- Free cash flow yield
- 2.51%
Fundamentals
- Revenue
- $754.05M
- Net income
- $73.06M
- EPS, diluted
- $0.90
- Free cash flow
- $164.23M
- Book value per share
- $7.35
- Diluted shares
- 82M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$754.05M+56.7% YoY
Gross profit
$673.44M+63.1% YoY
Operating income
$93.22M
Net income
$73.06M
EPS, diluted
$0.90
Free cash flow
$164.23M+275.5% YoY
Reported periodTrailing twelve months